Drug Detail

Information about GDC-0980

Generic Name
Brand Name (US)
Genentech/Piramed Ltd.
Drug Type
Kinase inhibitor
Approval Status
Phase 1
Overall Strategy
Oncogenic Signal Path Based
Block KIT Signal Path
Drug Category
PI3K inhibitor + mTOR inhibitor

GDC-0980 is a potent, selective, oral inhibitor of PI3K and mTOR.
Targeting signals downstream from KIT and PDGFRA is one strategy being investigated for Gleevec-resistant GIST and for many cancers in general. One of the most promising downstream targets appears to be PI3K. Some research suggests that inhibiting PI3K and mTOR may be more effective than inhibiting PI3K alone.
Development Status
Phase I clinical trials evaluating GDC-0980 for solid tumors or non-Hodgkin's lymphoma are ongoing. Phase Ib clinical trials evaluating GDC-0980 in combination with targeted medicines, Avastin® (bevacizumab), Herceptin® (trastuzumab), and Xeloda® (capecitabine) are ongoing or planned. A Phase II clinical trial evaluating both GDC-0941 and GDC-0980 for second-line ER-positive metastatic breast cancer and a Phase II clinical trial in renal cell carcinoma are planned.

This molecule was discovered jointly by Genentech and Piramed Ltd. under a collaboration agreement. Piramed Ltd. was acquired by F. Hoffmann-La Roche.